Morohashi, Hajime
Hakamada, Kenichi
Kanno, Takahiro
Kawashima, Kenji
Akasaka, Harue
Ebihara, Yuma
Oki, Eiji
Hirano, Satoshi
Mori, Masaki
Funding for this research was provided by:
Japan Agency for Medical Research and Development (Grant Number JP21hs0122001h0002)
Article History
Received: 3 June 2021
Accepted: 26 July 2021
First Online: 20 October 2021
Declarations
:
: Kenji Kawashima is employed by Riverfield and owns stock in the company. Takahiro Kannno is employed by Riverfield and serves as CTO. Hajime Morohashi and his co-authors have no conflicts of interest to declare.